Fenofibrate and Propranolol in Burn Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any - 80 |
| Updated: | 9/13/2018 |
| Start Date: | November 2015 |
| End Date: | December 2022 |
| Contact: | Catherine Reed, RN |
| Email: | ca2reed@utmb.edu |
| Phone: | 409-771-6987 |
Mechanisms of Fenofibrate and Propranolol Alone or Combined in Burn Patients
The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate
plus propranolol have therapeutic, physiological, and metabolic effects that will improve
clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.
plus propranolol have therapeutic, physiological, and metabolic effects that will improve
clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.
Determine the clinical benefits and underlying mechanisms whereby the metabolic perturbators
fenofibrate and propranolol impact burn patient outcomes. The investigators hypothesize that
these metabolic regulators given for one year will maintain body mass, improve muscle
function by increasing protein synthesis, augment wound healing, reduce fibrosis, improve
cardiovascular function, reduce systemic inflammation, restore insulin sensitivity, and
decrease liver dysfunction without the risk of the hypoglycemia.
fenofibrate and propranolol impact burn patient outcomes. The investigators hypothesize that
these metabolic regulators given for one year will maintain body mass, improve muscle
function by increasing protein synthesis, augment wound healing, reduce fibrosis, improve
cardiovascular function, reduce systemic inflammation, restore insulin sensitivity, and
decrease liver dysfunction without the risk of the hypoglycemia.
Inclusion Criteria:
- 0 through 80 years
- ≥ 20% Total Body Surface Area Burn injury
Exclusion Criteria:
Pregnancy
History or existence of pre-burn injury conditions
- Allergies to propranolol or fenofibrate
- Asthma requiring treatment
- Congestive heart failure (measured ejection fraction < 20%)
- Renal or hepatic disease
- Medical condition requiring glucocorticoid treatment
- History of AIDS, Aids Related Complex or HIV
- History of Cancer within 5 years
Decision not to treat due to burn injury severity or futility as deemed by the clinical
team
We found this trial at
1
site
Galveston, Texas 77555
Principal Investigator: David N Herndon, MD
Phone: 409-770-6987
Click here to add this to my saved trials
